(4R)-4-propan-2-yl-1,3-dioxolane

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氧戊环
• 英文名称: (4R)-4-propan-2-yl-1,3-dioxolane
• 化学式: C₆H₁₂O₂
• 分子量: 116.16
• InChiKey: TZHPBZXDBVUAMJ-LURJTMIESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• PREPARATION OF (R)-N-(3,4-DIFLUORO-2-(2-FLUORO-4-IODOPHENYLAMIN0)-6-METHOXYPHENYL)-1-(2,3-DIHYDROXYPROPYL)CYCLOPROPANE-1-SULFONAMIDE AND (S)- N-(3,4-DIFLUORO-2-(2-FLUORO-4-IODOPHENYLAMIN0)-6-METHOXYPHENYL)-1-(2,3-DIHYDROXYPROPYL)CYCLOPROPANE-1-SULFONAMIDE
  申请人：Maderna Andreas

  公开号：US20120178946A1

  公开（公告）日：2012-07-12

  The present invention relates to the preparation of (R)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide.

  本发明涉及制备(R)-N-(3,4-二氟-2-(2-氟-4-碘苯氨基)-6-甲氧基苯基)-1-(2,3-二羟基丙基)环丙烷-1-磺酰胺和(S)-N-(3,4-二氟-2-(2-氟-4-碘苯氨基)-6-甲氧基苯基)-1-(2,3-二羟基丙基)环丙烷-1-磺酰胺的方法。
• PREPARATION OF (R)-N-(3,4-DIFLUORO-2-(2-FLUORO-4-IODOPHENYLAMINO)-6-METHOXYPHENYL)-1-(2,3-DIHYDROXYPROPYL)CYCLOPROPANE-1-SULFONAMIDE AND (S)- N-(3,4-DIFLUORO-2-(2-FLUORO-4-IODOPHENYLAMINO)-6-METHOXYPHENYL)-1-(2,3-DIHYDROXYPROPYL)CYCLOPROPANE-1-SULFONAMIDE
  申请人：ARDEA BIOSCIENCES, INC.

  公开号：US20130261320A1

  公开（公告）日：2013-10-03

  The present invention relates to the preparation of (R)—N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and (S)—N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide.

  本发明涉及制备(R)-N-(3,4-二氟-2-(2-氟-4-碘苯基氨基)-6-甲氧基苯基)-1-(2,3-二羟基丙基)环丙烷-1-磺酰胺和(S)-N-(3,4-二氟-2-(2-氟-4-碘苯基氨基)-6-甲氧基苯基)-1-(2,3-二羟基丙基)环丙烷-1-磺酰胺的方法。
• MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
  申请人：Miller Mark Thomas

  公开号：US20170196862A2

  公开（公告）日：2017-07-13

  The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R 1 , R 2 , R 3 , W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.
• US8513443B2
  申请人：——

  公开号：US8513443B2

  公开（公告）日：2013-08-20
• US8884058B2
  申请人：——

  公开号：US8884058B2

  公开（公告）日：2014-11-11